Recombinant Human GAD65 Uses, Dosage, Side Effects and more
Recombinant Human GAD65 (recombinant human glutamic acid decarboxylase) is a vaccine being developed to treat insulin dependent type 1 diabetes.
The immune system of patients treated with Recombinant Human GAD65 demonstrate an increase in the secretion of several immunomodulatory substances, dominated by regulatory cytokines, including IL5, IL13, IL10, IL17, IFN-a and TNF-a. Additionally, the activity of T-cells in response to GAD65 is increased with Recombinant Human GAD65 therapy and subjects receiving Recombinant Human GAD65 show an up regulation of cytokines in response to GAD65.
| Attribute | Details |
|---|---|
| Trade Name | Recombinant Human GAD65 |
| Generic | rhGAD65 |
| rhGAD65 Other Names | Recombinant human GAD65, Recombinant human glutamic acid decarboxylase |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in diabetes mellitus type 1.
